TY - JOUR
T1 - Allo-anti-M
T2 - Detection peaks around 2 years of age, but may be attenuated by red blood cell transfusion
AU - for the Pediatric RBC Alloimmunization Consortium
AU - Tamai, Yoshiko
AU - Ohto, Hitoshi
AU - Yasuda, Hiroyasu
AU - Takeshita, Akihiro
AU - Fujii, Nobuharu
AU - Ogo, Hiroaki
AU - Yazawa, Yurika
AU - Hato, Takaaki
AU - Mitani, Kinuko
AU - Suzuki, Keijiro
AU - Yokohama, Akihiko
AU - Kato, Yoko
AU - Abe, Misao
AU - Kumagawa, Midori
AU - Ueda, Yasunori
AU - Nollet, Kenneth E.
AU - Cooling, Laura
AU - Kitazawa, Junichi
N1 - Funding Information:
We thank the following investigators who supported this study. Dr Hideto Takahashi (National Institute of Public Health), Ms Naomi Yachida (Tokyo Metropolitan Children's Medical Center), Mr Yasukazu Doi (Ehime University Hospital), Ms Junko Takadate (Iwate Medical University), Mr Shigeru Shinohara (Dokkyo Medical University Hospital), Mr Takayuki Marubashi (Gunma University Hospital), Dr Tetsunori Tasaki (The Jikei University School of Medicine Hospital), Mr Yoshihiro Yabuta (Kurashiki Central Hospital), Dr Minami Yamada-Fujiwara and Ms Ayuko Narita (Tohoku University Hospital), Ms Maiko Abe-Yamada and Ms Kinuyo Kawabata (Fukushima Medical University Hospital), Dr Koji Yamamoto and Mr Masahiro Anan (Saitama Medical University Saitama Medical Center), Dr Toshiyuki Ikeda, Mr Yutaka Nagura and Dr Hitoshi Okazaki (The University of Tokyo Hospital), Ms Kayoko Kimura and Dr Shohei Yamamoto (Showa University Fujigaoka Hospital), Dr Soranobu Ninomiya (Gifu University Hospital), Mr Masahiro Ueda and Ms Ikuyo Hayakawa (Kobe University Hospital), Mr Yuki Hatayama and Dr Toru Motokura (Tottori University Hospital), Dr Yoshitaka Furukawa and Ms Tamaka Miyamoto (Kagoshima University Hospital), Mr Yo Taniguchi (National Hospital Organization Nagoya Hospital Center), Dr Asayuki Iwai, Ms Kumiko Hiraoka (Shikoku Medical Center for Children and Adults), and Mr Hiroaki Nagashima (Hokkaido Medical Center for Child Health and Rehabilitation).
Publisher Copyright:
© 2021 The Authors. Transfusion published by Wiley Periodicals LLC on behalf of AABB.
PY - 2021/9
Y1 - 2021/9
N2 - Background: Anti-M is frequently observed as a naturally occurring antibody of little clinical significance. Naturally occurring anti-M is often found in children although the specific triggers of production, persistence, and evanescence of anti-M have yet to be elucidated. Methods: In a retrospective, multicenter, nationwide cohort survey conducted from 2001 to 2015, alloantibody screening was performed before and after transfusion in 18,944 recipients younger than 20 years. Recipients were categorized into six cohorts based on their age at transfusion; within and among these cohorts, allo-anti-M was analyzed in regard to its production, persistence, and evanescence. Results: In 44 patients, anti-M detected before and/or after transfusion was an age-related phenomenon, with a median age of 2 years and an interquartile range of 1–3 years; anti-M was most frequently detected in a cohort of children 1 to <5 years (0.77%, 31 of 4035). At least five patients were presumed to have concurrent infections. Among 1575 adolescents/young adults (15 to <20 years), no anti-M was detected. Of 29 patients with anti-M prior to transfusion, the antibody fell to undetectable levels in 17 recipients (89.5%, of whom at least 13 received only M-negative red cells) after anywhere from 5 days to 5.8 years; anti-M persisted in 2, and was not tested in 10. Only 15 recipients (0.08%) produced new anti-M after transfusion. Conclusion: Naturally occurring anti-M is a phenomenon of younger ages, predominantly between 1 and 3 years. After transfusion, it often falls to undetectable levels.
AB - Background: Anti-M is frequently observed as a naturally occurring antibody of little clinical significance. Naturally occurring anti-M is often found in children although the specific triggers of production, persistence, and evanescence of anti-M have yet to be elucidated. Methods: In a retrospective, multicenter, nationwide cohort survey conducted from 2001 to 2015, alloantibody screening was performed before and after transfusion in 18,944 recipients younger than 20 years. Recipients were categorized into six cohorts based on their age at transfusion; within and among these cohorts, allo-anti-M was analyzed in regard to its production, persistence, and evanescence. Results: In 44 patients, anti-M detected before and/or after transfusion was an age-related phenomenon, with a median age of 2 years and an interquartile range of 1–3 years; anti-M was most frequently detected in a cohort of children 1 to <5 years (0.77%, 31 of 4035). At least five patients were presumed to have concurrent infections. Among 1575 adolescents/young adults (15 to <20 years), no anti-M was detected. Of 29 patients with anti-M prior to transfusion, the antibody fell to undetectable levels in 17 recipients (89.5%, of whom at least 13 received only M-negative red cells) after anywhere from 5 days to 5.8 years; anti-M persisted in 2, and was not tested in 10. Only 15 recipients (0.08%) produced new anti-M after transfusion. Conclusion: Naturally occurring anti-M is a phenomenon of younger ages, predominantly between 1 and 3 years. After transfusion, it often falls to undetectable levels.
KW - anti-M
KW - child
KW - infection
KW - naturally occurring antibody
UR - http://www.scopus.com/inward/record.url?scp=85115063357&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85115063357&partnerID=8YFLogxK
U2 - 10.1111/trf.16594
DO - 10.1111/trf.16594
M3 - Article
AN - SCOPUS:85115063357
SN - 0041-1132
VL - 61
SP - 2718
EP - 2726
JO - Transfusion
JF - Transfusion
IS - 9
ER -